This Week on Life Sciences Digital
On Tuesday, June 30, at an "AI for Science" event in San Francisco, Anthropic launched Claude Science, its first product built specifically for biopharmaceutical research, and confirmed it will run internal drug discovery programs on neglected diseases using the same tool. Two announcements, one strategic message: Anthropic is no longer just selling foundation models to pharma. It is building the operating layer for scientific research, and using that layer itself.
Claude Science is not a new model. It runs on Claude Opus 4.8, available to Pro, Max, Team, and Enterprise subscribers with no additional gating. What is new is the environment around the model. Anthropic has connected more than 60 scientific databases into a single workbench, with pre-loaded toolkits for genomics, single-cell analysis, proteomics, structural biology, and cheminformatics. A central AI assistant acts as project manager, spawning specialised sub-agents for individual research tasks. A separate fact-checker agent verifies citations and calculations before results leave the environment. Named early customers include Novo Nordisk, the Allen Institute, and Manifold Bio. Stephen Francis's group at the UCSF Brain Tumor Center demonstrated germline analysis of gliomas compressed from days to hours.
The second announcement is more consequential for how the market is being reshaped. Head of Life Sciences Eric Kauderer-Abrams confirmed Anthropic will pursue its own drug candidates for diseases that traditional pharma considers commercially unattractive. The reasoning is not purely humanitarian. Anthropic needs first-hand experience running the workflows it sells, and neglected disease programs give it a low-competition sandbox to learn from. This positions Anthropic simultaneously as a vendor to pharma, a partner to academic labs, and a discovery organisation in its own right.
Markets responded immediately. Schrödinger shares fell up to 8.3% intraday. Recursion Pharmaceuticals also traded sharply lower before partial recovery. The signal both stocks were reacting to is that a frontier AI lab, with foundation model access no incumbent can match, has just entered the same lane. Anthropic is also offering up to $30,000 in credits for up to 50 research projects, with applications open until July 15 for early-stage postdoctoral and graduate work.
Generated with NotebookLM
Also This Week:
Roughly $60M in upfront and near-term payments, up to $600M in milestones, tiered royalties on future sales. This is Takeda's second publicly disclosed AI platform deal of 2026 after the up to $1.7B Iambic Therapeutics collaboration in February. Insilico's cumulative disclosed 2026 contract value now sits near $6.5B across Eli Lilly, SK Biopharmaceuticals, Servier, Fosun, Qilu, China Medical System, and Takeda. The AI drug discovery layer is consolidating around a small number of platform engines, and top-20 pharma is racing to lock one in.
169 cross-border licensing deals, $93B in total disclosed value, up 87% year-on-year. Latest example: Metis TechBio's global licensing deal with Boulevard Bio for MTS-128, an AI-designed oncology candidate, at $20M upfront and up to $1.6B in milestones. US scrutiny of Chinese biotech is rising, but the capital flowing into Chinese AI-native discovery is not slowing.
On June 29 the Council formally adopted the Digital Omnibus on AI. Publication in the Official Journal is expected imminently, with the regulation entering force three days after publication. The revised application dates are now fixed: 2 December 2027 for stand-alone Annex III high-risk systems, and 2 August 2028 for AI embedded in regulated products, including medical devices and IVDs. The Commission also gains power to limit duplicative requirements where MDR and IVDR already cover equivalent obligations. Manufacturers gain time, but the direction of travel is confirmed.
Revvity Signals Software now exposes its governed R&D data and ontologies through MCP, letting scientists query Signals AI capabilities directly from inside Claude, including Claude Science. This is the pattern to watch. When enterprise data vendors publish MCP connectors, they become interoperable with any Claude-based workflow overnight. Expect other established R&D platforms to follow before Q4.
Snowflake's AI Data Cloud can now legally host French health data workloads across EEA regions, an important unlock for research teams that have historically had to keep clinical data on separate on-premise infrastructure. Sanofi already runs real-world clinical data processing on Snowflake. HDS matters beyond France as European Health Data Space implementation moves forward and other Member States tighten health data hosting rules.
Greenlight Guru achieves ISO 42001 certification for AI governance across its eQMS and EDC products 🔗
First medtech-focused vendor to publicly announce ISO 42001 covering both quality management and electronic data capture. Certifications like this are becoming vendor-qualification requirements as FDA and EU regulators formalise AI governance expectations. Procurement teams will start asking for this on RFPs before year-end.
Median Technologies obtains CE marking for eyonis LCS, an AI-based Software as a Medical Device for lung cancer screening 🔗
Granted by GMED under MDR 2017/745 as a Class IIb device, following the FDA 510(k) clearance in February. eyonis LCS combines computer-aided detection and diagnosis in the LDCT lung cancer screening pathway, targeting 25 to 30 million eligible individuals across the EU. Notable as a rare example of an AI/ML SaMD clearing the full MDR pathway ahead of the AI Act's application to embedded high-risk systems.
Tool Spotlight from our Life Sciences Digital database
FutureHouse Platform
RESEARCH INTELLIGENCE & DISCOVERY
Nonprofit-run platform of autonomous AI agents built specifically for scientific research, with a public interface for tasks like literature search, hypothesis generation, and end-to-end discovery workflows. Sits in the same category Claude Science just entered, but with open access for academic researchers.
🚀 Your solution, in front of the people building the future of life sciences
🎯 Reach over 30,000 professionals through our partnership with bionity.com
Events & Calls
The Bioprocessing Summit — Boston, August 10–13
Focused on cell and gene therapy manufacturing and commercialization, an area where 167 tools in our database fall under Drug Discovery & Molecular Design.
ESC Congress 2026 — Munich, August 28–31
The world's largest cardiology meeting is built around a "Spotlight on Artificial Intelligence" theme this year, covering AI as a co-pilot across diagnosis, treatment, and clinical workflows.
NVIDIA GTC — Berlin, October 20–22
Sessions will span the five-layer AI stack from the hardware components to the industries being transformed by physical AI, and more.
🤝 Got a tool for life sciences you'd like more people to know about?
Submit your tool here.
Want to be featured in a future issue or explore sponsorship?
We highlight the AI tools, companies, and initiatives shaping the future of life sciences. If you'd like to collaborate, reply to this email or get in touch: [email protected]
